Therefore, SMAD2 upregulation mediated the anti-tumor effect of ITGA2 silencing in pancreatic cancer, which represents treatment by inducing the SMAD2 expression as a novel therapeutic strategy for pancreatic cancer. This evidence concerns the gene ITGA2 and familial pancreatic carcinoma.